Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that four ...
Exscientia researchers combined '565 with the BTK inhibitor zanubrutinib and observed deeper, more durable efficacy responses in xenograft models of B-cell malignancies, with long-lasting tumour ...
Full abstracts accepted as poster presentations will also be included in the special CTAD edition of the Journal of Prevention of Alzheimer’s Disease (JPAD), the official journal of the CTAD ...
We've found a selection of fonts great for presentations. Most of these are standard system fonts in PowerPoint and many are included in the Windows or Mac ... Then you'll want a font to match, and ...
today announced one oral and two poster presentations at the 20 th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal taking place on October 6-9, 2024. Venkat Krishnamurthy, Ph.D.